Scipher Medicine is a spin-out of Northeastern University founded on the basis of, first, building a map of human biology called the Human Interactome that explains how proteins expressed from genes interact to cause specific disease phenotypes and, second, developing computational tools needed to interpret the genetic list developed by the Human Genome Project. Building on that founding work, Scipher Medicine developed PrismRA® as a new molecular signature test that assesses the likelihood that a patient with RA may not respond to a TNFi therapy before said patient starts a targeted treatment for the first time.